Imel Therapeutics KK, one of Remiges Ventures' portfolio companies, has been selected for the 'Drug Discovery Venture Ecosystem Enhancement Project' by AMED, which provides grants

News > Imel Therapeutics KK, one of Remiges Ventures' portfolio companies, has been selected for the "Drug Discovery Venture Ecosystem Enhancement Project" by AMED, which provides grants

Imel Therapeutics KK, one of Remiges Ventures' portfolio companies, has been selected for the "Drug Discovery Venture Ecosystem Enhancement Project" by AMED, which provides grants

12/01/2023

Imel Therapeutics KK, one of Remiges Ventures' portfolio companies, has been selected for the "Drug Discovery Venture Ecosystem Enhancement Project" by AMED, which provides grants.

In this project, the Japan Agency for Medical Research and Development (AMED) certifies venture capital firms that offer hands-on support specializing in drug discovery and development for their portfolio companies. The program supports the development and commercialization of drug discovery programs with matching grants.

Imel Therapeutics KK is a startup company that develops therapeutics for diseases related to mitochondrial gene abnormalities and aging. The company utilizes mitochondrial DNA (mtDNA) replacement technology discovered by Professor Rishi Gojo of Kyoto Prefectural University of Medicine and his colleagues.

• AMED

For more detailed information please visit the above AMED web pages.